Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong

Published:2017-05-30 Issue:6 Volume:32 Page:1230-1233
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Chan Henry Lik‐Yuen¹,Tsang Owen Tak‐Yin²,Hui Yee‐Tak³,Fung James⁴,Lui Grace Chung‐Yan¹,Lai Ching‐Lung⁴,Wong Grace Lai‐Hung¹,Chan Kam‐Hon⁵,But David Yiu‐Kuen⁴,Lai Moon‐Sing⁵,Lao Wai‐Cheung⁶,Chan Carmen Ka‐Man¹,Lam Yip‐Shun³,Seto Wai‐Kay⁴,Li Carlton³,Yuen Man‐Fung⁴,Wong Vincent Wai‐Sun¹

Affiliation:

1. Department of Medicine and Therapeutics and Institute of Digestive DiseaseThe Chinese University of Hong Kong Hong Kong

2. Department of Medicine and GeriatricsPrincess Margaret Hospital Hong Kong

3. Department of MedicineQueen Elizabeth Hospital Hong Kong

4. Department of Medicine, The University of Hong KongQueen Mary Hospital Hong Kong

5. Department of MedicineNorth District Hospital Hong Kong

6. Department of MedicinePamela Youde Nethersole Eastern Hospital Hong Kong

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.13663

Reference15 articles.

1. From non-A, non-B hepatitis to hepatitis C virus cure

2. Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital

3. ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

4. ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

5. ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania;Medical Science Monitor;2022-06-23

2. HCV elimination in Hong Kong – Non-government organisation (NGO) activities;Global Health & Medicine;2021-10-31

3. Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong;Digestive Diseases and Sciences;2020-05-08

4.

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

;Infection and Drug Resistance;2019-07

5. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis;Scientific Reports;2019-05-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3